Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: A case report

Yousuke Higuchi, Takayuki Motoki, Hisashi Ishida, Kiichiro Kanamitsu, Kana Washio, Takanori Oyama, Takuo Noda, Yasuko Tsurumaru, Ayumi Okada, Hirokazu Tsukahara, Akira Shimada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Pediatric papillary thyroid carcinoma frequently presents with lymph node involvement and distant metastases. Sorafenib, an oral multikinase inhibitor, has been used to treat radioactive iodine (RAI) therapy-refractory thyroid carcinoma in adults; however, pediatric experience is limited. Medical procedures and hospitalization for children with autism spectrum disorder may be challenging. Case presentation: An 11-year-old boy with autism spectrum disorder and moderate intellectual impairment presented with dyspnea on exertion with thyroid carcinoma and diffuses lung metastases. Total thyroidectomy and adjuvant RAI therapy is the standard treatment; however, the latter therapy was impractical because of his respiratory status and challenging behaviors. He was therefore started on sorafenib 200 mg/day (150 mg/m2/day) and this dosage was increased to 400 mg/day (300 mg/m2/day). The adverse effects were mild and tolerable. After administration of medication, his dyspnea improved and surgery was performed. We attempted to administer RAI therapy after surgery; however, we abandoned it because he had difficulty taking care of himself according to isolation room rules. Thyrotropin suppression therapy was therefore started and sorafenib treatment (400 mg/day) resumed. Follow-up imaging showed regression of pulmonary metastases. The metastases have remained stable for over 24 months on continuous sorafenib treatment without serious adverse events. Conclusion: We inevitably used sorafenib as an alternative to standard therapy because of the patient's specific circumstances. Individualized strategies for pediatric cancer patients with autism spectrum disorder are needed.

Original languageEnglish
Article number775
JournalBMC Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - Nov 21 2017

Fingerprint

Neoplasm Metastasis
Lung
Iodine
Therapeutics
Pediatrics
Thyroid Neoplasms
Dyspnea
sorafenib
Papillary Thyroid cancer
Autism Spectrum Disorder
Thyroidectomy
Thyrotropin
Hospitalization
Lymph Nodes
Neoplasms

Keywords

  • Autism spectrum disorder
  • Lung metastases
  • Papillary thyroid carcinoma
  • Pediatrics
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder : A case report. / Higuchi, Yousuke; Motoki, Takayuki; Ishida, Hisashi; Kanamitsu, Kiichiro; Washio, Kana; Oyama, Takanori; Noda, Takuo; Tsurumaru, Yasuko; Okada, Ayumi; Tsukahara, Hirokazu; Shimada, Akira.

In: BMC Cancer, Vol. 17, No. 1, 775, 21.11.2017.

Research output: Contribution to journalArticle

@article{63923f820a67419b99722393599f9b47,
title = "Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: A case report",
abstract = "Background: Pediatric papillary thyroid carcinoma frequently presents with lymph node involvement and distant metastases. Sorafenib, an oral multikinase inhibitor, has been used to treat radioactive iodine (RAI) therapy-refractory thyroid carcinoma in adults; however, pediatric experience is limited. Medical procedures and hospitalization for children with autism spectrum disorder may be challenging. Case presentation: An 11-year-old boy with autism spectrum disorder and moderate intellectual impairment presented with dyspnea on exertion with thyroid carcinoma and diffuses lung metastases. Total thyroidectomy and adjuvant RAI therapy is the standard treatment; however, the latter therapy was impractical because of his respiratory status and challenging behaviors. He was therefore started on sorafenib 200 mg/day (150 mg/m2/day) and this dosage was increased to 400 mg/day (300 mg/m2/day). The adverse effects were mild and tolerable. After administration of medication, his dyspnea improved and surgery was performed. We attempted to administer RAI therapy after surgery; however, we abandoned it because he had difficulty taking care of himself according to isolation room rules. Thyrotropin suppression therapy was therefore started and sorafenib treatment (400 mg/day) resumed. Follow-up imaging showed regression of pulmonary metastases. The metastases have remained stable for over 24 months on continuous sorafenib treatment without serious adverse events. Conclusion: We inevitably used sorafenib as an alternative to standard therapy because of the patient's specific circumstances. Individualized strategies for pediatric cancer patients with autism spectrum disorder are needed.",
keywords = "Autism spectrum disorder, Lung metastases, Papillary thyroid carcinoma, Pediatrics, Sorafenib",
author = "Yousuke Higuchi and Takayuki Motoki and Hisashi Ishida and Kiichiro Kanamitsu and Kana Washio and Takanori Oyama and Takuo Noda and Yasuko Tsurumaru and Ayumi Okada and Hirokazu Tsukahara and Akira Shimada",
year = "2017",
month = "11",
day = "21",
doi = "10.1186/s12885-017-3782-7",
language = "English",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder

T2 - A case report

AU - Higuchi, Yousuke

AU - Motoki, Takayuki

AU - Ishida, Hisashi

AU - Kanamitsu, Kiichiro

AU - Washio, Kana

AU - Oyama, Takanori

AU - Noda, Takuo

AU - Tsurumaru, Yasuko

AU - Okada, Ayumi

AU - Tsukahara, Hirokazu

AU - Shimada, Akira

PY - 2017/11/21

Y1 - 2017/11/21

N2 - Background: Pediatric papillary thyroid carcinoma frequently presents with lymph node involvement and distant metastases. Sorafenib, an oral multikinase inhibitor, has been used to treat radioactive iodine (RAI) therapy-refractory thyroid carcinoma in adults; however, pediatric experience is limited. Medical procedures and hospitalization for children with autism spectrum disorder may be challenging. Case presentation: An 11-year-old boy with autism spectrum disorder and moderate intellectual impairment presented with dyspnea on exertion with thyroid carcinoma and diffuses lung metastases. Total thyroidectomy and adjuvant RAI therapy is the standard treatment; however, the latter therapy was impractical because of his respiratory status and challenging behaviors. He was therefore started on sorafenib 200 mg/day (150 mg/m2/day) and this dosage was increased to 400 mg/day (300 mg/m2/day). The adverse effects were mild and tolerable. After administration of medication, his dyspnea improved and surgery was performed. We attempted to administer RAI therapy after surgery; however, we abandoned it because he had difficulty taking care of himself according to isolation room rules. Thyrotropin suppression therapy was therefore started and sorafenib treatment (400 mg/day) resumed. Follow-up imaging showed regression of pulmonary metastases. The metastases have remained stable for over 24 months on continuous sorafenib treatment without serious adverse events. Conclusion: We inevitably used sorafenib as an alternative to standard therapy because of the patient's specific circumstances. Individualized strategies for pediatric cancer patients with autism spectrum disorder are needed.

AB - Background: Pediatric papillary thyroid carcinoma frequently presents with lymph node involvement and distant metastases. Sorafenib, an oral multikinase inhibitor, has been used to treat radioactive iodine (RAI) therapy-refractory thyroid carcinoma in adults; however, pediatric experience is limited. Medical procedures and hospitalization for children with autism spectrum disorder may be challenging. Case presentation: An 11-year-old boy with autism spectrum disorder and moderate intellectual impairment presented with dyspnea on exertion with thyroid carcinoma and diffuses lung metastases. Total thyroidectomy and adjuvant RAI therapy is the standard treatment; however, the latter therapy was impractical because of his respiratory status and challenging behaviors. He was therefore started on sorafenib 200 mg/day (150 mg/m2/day) and this dosage was increased to 400 mg/day (300 mg/m2/day). The adverse effects were mild and tolerable. After administration of medication, his dyspnea improved and surgery was performed. We attempted to administer RAI therapy after surgery; however, we abandoned it because he had difficulty taking care of himself according to isolation room rules. Thyrotropin suppression therapy was therefore started and sorafenib treatment (400 mg/day) resumed. Follow-up imaging showed regression of pulmonary metastases. The metastases have remained stable for over 24 months on continuous sorafenib treatment without serious adverse events. Conclusion: We inevitably used sorafenib as an alternative to standard therapy because of the patient's specific circumstances. Individualized strategies for pediatric cancer patients with autism spectrum disorder are needed.

KW - Autism spectrum disorder

KW - Lung metastases

KW - Papillary thyroid carcinoma

KW - Pediatrics

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85034653810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034653810&partnerID=8YFLogxK

U2 - 10.1186/s12885-017-3782-7

DO - 10.1186/s12885-017-3782-7

M3 - Article

C2 - 29162036

AN - SCOPUS:85034653810

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 775

ER -